Sales growth of 15.7% in first-half 2020

Robust growth in contributive operating income before non-recurring items, to 17.1% of sales

"In today’s unprecedented health crisis, bioMérieux’s positioning as a specialist in infectious disease diagnostics takes on all of its meaning and allowed to rapidly provide high-performance solutions for diagnosing COVID-19." Alexandre Mérieux, Chairman & CEO

Contact us